Clinical Trials

3 studies in Amyloidosis

1. Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation Rochester, MN View Summary
   Close

   Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   1. How does age at diagnosis affect prognosis in primary amyloidosis? 2. How do lab values at diagnosis such as Creatinine, AST/ALT, total serum protein, serum gamma globulin/immunoglobulin levels affect prognosis in primary amyloidosis? 3. How does degree of organ involvement/number of organs involved affect prognosis in primary amyloidosis? 4. How does initial treatment affect prognosis in primary amyloidosis? 4. How do the specifics the stem cell transplant protocol affect prognosis in primary amyloidosis?

   NCT ID:

   NCT01606280

   IRB Number:

   11-005003

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Moire Gertz, MD 507-284-3725
                       
   
   
   

   Request Information Online
2. Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis Scottsdale and Phoenix, AZ Rochester, MN View Summary
   Close

   Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

   Location:

   Scottsdale and Phoenix, AZ Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   This is a phase 3, randomized, controlled, open-label, multicenter study of the oral formulation of dexamethasone plus MLN9708 compared with treatment chosen by the investigator from a prespecified list of regimens available in clinical practice. Treatment options will include: dexamethasone alone, dexamethasone plus an alkylating agent (melphalan or cyclophosphamide), or dexamethasone plus an immunomodulatory drug (IMiD, thalidomide or lenalidomide) in patients with relapsed or refractory AL amyloidosis. Crossover to the investigational treatment arm is not permitted during participation in this study.

   NCT ID:

   NCT01659658

   IRB Number:

   12-005223

   • Print Summary
   • View study details
3. Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Rochester, MN View Summary
   Close

   Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   The purpose of the dose escalation phase of the study is to determine the maximum tolerated dose/Phase 2 recommended dose of NEOD001 when given as a single agent intravenously in approximately 30 subjects with AL amyloidosis. The purpose of the expansion phase of the study is to evaluate the safety, preliminary efficacy and pharmacokinetics of single agent NEOD001 at the maximum tolerated dose/Phase 2 recommended dose in approximately 20 additional evaluable subjects.

   NCT ID:

   NCT01707264

   IRB Number:

   12-007863

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Ann Birgin, CRA 507-284-8828
                       
   
   
   

   Request Information Online